Haemopoietic growth factors for neonates: Assessing risks and benefits

Acta Paediatrica, International Journal of Paediatrics, Supplement

Volumn 93, Issue 444, 2004, Pages 15-19

  Carr, R ^a   Modi, N ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Erythropoietin; Granulocyte colony stimulating factor; Granulocyte macrophage colony stimulating factor; Neonate; Thrombopoietin

Indexed keywords

HEMOPOIETIC GROWTH FACTOR; RECOMBINANT COLONY STIMULATING FACTOR 1; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT THROMBOPOIETIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY PRODUCTION; CANCER INCIDENCE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOPENIA; GESTATIONAL AGE; HIGH RISK PATIENT; HUMAN; INFANT MORTALITY; MEGAKARYOPOIESIS; NEUTROPENIA; NEWBORN; NEWBORN PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEPSIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 1242338083     PISSN: 08035326     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2004.tb03042.x     Document Type: Conference Paper

References (32)

1. Shannon KM, Keith JF, Mentzer WC. Recombinant human erythopoietin stimulates erythopoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics 1995; 95: 1-8
2. Maier RF, Obladen M, Scigalla P. The effect of epoetin beta (recombinat human erythopoietin) on the need for transfusion in very low birth weight infants. N Engl J Med 1994; 330: 1173-8
3. Soubasi V, Kremenopoulos G, Diamanti E, Tsantali C, Sarafidis K, Tsakiris D. Follow-up of very low birth weight infants after erythropoietin to prevent anaemia of prematurity. J Pediatr 1995; 127: 291-7
4. Ohls RK, Ehrenkranz RA, Wright LL, Lemons JA, Korones SB, Stoll BS, et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight. A multicentre, randomised, controlled trial. Pediatrics 2001; 108: 934-42
5. Ohls RK. The use of erythropoietin in neonates. Clin Perinatol 2000; 27: 681-96
6. Watts TL, Murray NA, Roberts IAG. Thrombopoietin has a primary role in the regulation of platelet production in preterm babies. Pediatr Res 1999; 46: 28-32
7. Sola MC, Dame C, Christensen RD. Towards a rational use of recombinant thrombopoietin in the neonatal intensive care unit. J Pediatr Hematol Oncol 2000; 83: 160-64
8. Carr R, Huizinga TWJ. Low soluble FcRIII receptor demonstrates reduced neutrophil reserves in preterm neonates. Arch Dis Child Fetal Neonatal Ed 2001; 23: 179-84
9. Carr R. Neutrophil production and function in newborn infants. Br J Haematol 2000; 110: 18-28
10. Hill HR. The pathophysiology of neonatal neutrophil dysfunction. Pediatr Res 1999; 45: 761
11. Joyner JL, Augustine NH, Taylor KA, La Pine TR, Hill HR. Effects of group B streptococci on cord and adult mononuclear cell interleukin-12 and interferon-gama mRNA accumulation and protein secretion. J Infect Dis 2000; 182: 974-7
12. Gillan ER, Christensen RD, Yu Suen, Ellis R, van de Ven C, Cairo MS. A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia. Blood 1994; 84: 1427-33
13. Cairo MS, Christensen R, Sender LS, Ellis R, Rosenthal J, van de Ven C, et al. Results of a phase I/II trial of recombinant human granulocyte- macrophage colony-stimulating factor in very low birthweight neonates: significant induction of circulatory neutrophils, monocytes, platelets, and bone marrow neutrophils. Blood 1995; 86: 2509-15
14. Kocherlakota P, La Gamma EF. Human granulocyte colony-stimulating factor may improve outcome attributable to neonatal sepsis complicated by neutropenia. Pediatrics 1997; 100: E6
15. Kocherlakota P, La Gamma EF. Preliminary report: rhG-CSF may reduce the incidence of neonatal sepsis in prolonged preeclampsa-associated neutropenia. Pediatrics 1998; 102: 1107-11
16. Schibler KR, Osborne KA, Leung LY, Le TV, Baker SI, Thompson DD. A randomised, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis. Pediatrics 1998; 102: 6-13
17. Drossou-Agakidou V, Kanakoudi-Tsakalidou F, Sarafidis K, et al. Administration of recombinant human granulocyte-colony stimulating factor to septic neonates induces neutrophilia and enhances the neutrophil respiratory burst and beta2 integrin expression. Results of a randomised controlled trial. Eur J Pediatr 1998; 157: 583-8
18. Bedford Russell AR, Emmerson AJB. Wilkinson N, Chant T, Sweet DG, Halliday HL, et al. A trial of recombinant human granulocyte colony stimulating factor for the treatment of very low birthweight infants with presumed sepsis and neutropenia. Arch Dis Child Fetal Neonatal Ed 2000; 84: F172-6
19. Bilgin K, Yaramis A, Haspolat K, Tas A, Gunbey S, Derman O. A randomised trial of granulocyte-macrophage colony stimulating factor in neonates with sepsis and neutropenia. Pediatrics 2001; 107: 36-41
20. Muira E, Procianoy R, Bittar C, Miura CS, Mello C, Christensen RD. A randomised, double-masked, placebo controlled trial of recombinant Granulocyte colony stimulating factor administration to pretem infants with the clinical diagnosis of early-onset sepsis. Pediatrics 2001; 107: 30-5
21. La Gamma E, Welch W, Jeffs R. A multicentre, double-blind, randomised, placebo-cotrolled safety and efficacy study of filgrastim (rHuG-CSF) in the treament of late-onset neonatal sepsis. Pediatr Res 2000; 47: 2421 Abstr
22. Carr R, Modi N, Doré C, El-Rifai R, Lindo D. A randomized, controlled trial of prophylactic granulocyte-macrophage colony-stimulating factor in human newobrns less than 32 weeks gestation. Pediatrics 1999; 103: 796-802
23. Cairo MS, Agosti J, Ellis R, Laver J, Puppa B, deLemos R, et al. A randomised, double-blind, placebo-controlled trial of prophylactic recombinant human granulocyte-macrophage colony-stimulating factor to reduce nosocomial infections in very low birthweight neonates. J Pediatr 1999; 134: 64-70
24. Freedman MH, Alter BP. Risk of myelodysplastic syndrome and acute myeloid leukaemia in congenital neutropenias. Semin Hematol 2002; 39: 128-33
25. Dale DC, Boylard AA, Aprikyan A. Cyclic neutropenia. Semin Hematol 2002; 39: 89-94
26. Ohls RK, Christensen RD. Recombinant erythropoietin compared with erythrocyte transfusion in treatment for anaemia of prematurity. J Pediatr 1991; 119: 781-8
27. Bedford Russell AR, Dacies EG, Ball SE, Gordon Smith E. Granulocyte colony stimulating factor treatment for neonatal neutropenia. Arch Dis Child Fetal Neonatal Ed 1995; 72: F53-4
28. Rosenthal J, Healey T, Ellis R, Gillan E, Cairo MS. A two-year follow-up of neonates with presumed sepsis treated with recombinant human granulocyte colony-stimulating factor during the first week of life. J Pediatr 1996; 128: 135-7
29. Casadeva N, Nataaaf J, Viron B, Kolta A, Kiladjian J-J, Martin-Dupont P, et al. Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-5
30. Li J, Yang C, Bertino A, Glaspy J, Roberts M, Kuter DJ. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 3241-8
31. Larichia-Robbio L, Moscato S, Genna A, Liberati AM, Revoltella RP. Naturally occuring and therapy-induced antibodies to human granulocyte colony-stimulating factor (G-CSF) in human serum. J Cell Physiol 1997; 173: 219-26
32. Ragnhammar P, Heinz-Jürgen F, Frödin J-E, Lefvert A-K, Hassan M, Österborg A. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in non-immunocompromised patients. Blood 1994; 84: 4078-87